Loading clinical trials...
Loading clinical trials...
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib
Conditions
Interventions
Imatinib
Dasatinib
Locations
101
United States
Local Institution - 0004
Anaheim, California, United States
Local Institution - 0006
Fontana, California, United States
University Of Southern California University Hospital
Los Angeles, California, United States
Local Institution - 0110
Roseville, California, United States
Local Institution - 0112
San Jose, California, United States
Local Institution - 0009
Vallejo, California, United States
Start Date
September 12, 2012
Primary Completion Date
November 8, 2017
Completion Date
April 12, 2022
Last Updated
June 22, 2023
NCT03934372
NCT01914484
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions